Business context and reporting period
NeoGenomics, Inc. filed this Form 10-K for the fiscal year ended December 31, 2023. The company provides oncology diagnostic testing and consultative services through laboratories in the United States and United Kingdom. Clinical Services generated 84% of 2023 revenue; Advanced Diagnostics, serving pharmaceutical and biotech customers, generated 16%.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $591.6 million | $509.7 million |
| Gross profit / margin | $244.6 million / 41.3% | $187.9 million / 36.9% |
| Operating loss | $107.7 million | $157.6 million |
| Net loss | $88.0 million | $144.3 million |
| Net loss per diluted share | $0.70 | $1.16 |
| Adjusted EBITDA (non-GAAP) | $3.5 million | $(48.0) million |
| Cash used in operating activities | $2.0 million | $66.0 million |
Clinical Services revenue increased 18.4% to $495.6 million, attributed to higher test volume, favorable mix and improved average unit pricing. Advanced Diagnostics revenue rose 5.5% to $96.0 million. Gross margin improved 4.4 percentage points. Interest income increased to $16.9 million from $6.1 million, primarily reflecting higher rates.
At year-end, cash and cash equivalents were $342.5 million, marketable securities were $72.7 million, working capital was $500.5 million, and current liabilities were $96.3 million. Convertible notes had $546.3 million aggregate principal outstanding ($538.2 million net carrying value): $201.3 million due in 2025 and $345.0 million due in 2028. Management expects available cash, securities and collections to fund operating and capital needs for at least 12 months. Planned 2024 capital expenditures are $35–$40 million.
Changes versus the prior year
- Revenue grew 16.1%, while total cost of revenue rose 7.8%; gross profit increased 30.2%.
- Operating cash use improved by $64.0 million, mainly due to stronger gross profit and operating results.
- Net loss narrowed by $56.3 million; adjusted EBITDA improved by $51.5 million to positive territory.
- Restructuring charges rose to $11.1 million from $4.5 million. The company expects approximately $6.3 million of additional charges extending into 2024.
- Research and development expense decreased 9.9% to $27.3 million; management anticipates increased investment in future test development.
Outlook, risks and unusual items
The filing provides strategic priorities rather than quantified revenue or earnings guidance. For 2024, management plans to grow core testing volume and NGS mix, improve revenue-cycle management and margins, launch Neo Comprehensive 2.0 and liquid-biopsy comprehensive genomic profiling, improve productivity, and begin Phase 1 of a laboratory information management system implementation. Management does not anticipate significant 2024 clinical revenue changes from known legislation or rulemaking, while noting uncertainty around reimbursement and regulation.
- RaDaR litigation: A court granted Natera a preliminary injunction on December 27, 2023, restricting RaDaR use, with exceptions for certain existing patients, ongoing research and qualifying clinical trials. NeoGenomics appealed; the outcome and potential financial impact were not estimable at filing.
- Regulatory investigation: The company’s voluntary investigation into certain consulting and service agreements remains ongoing with the OIG and DOJ. It recorded an $11.2 million reserve for estimated minimum probable loss but could not estimate additional exposure.
- Regulatory and reimbursement risk: The FDA proposed a phased framework to regulate laboratory-developed tests; final timing and requirements were uncertain. Medicare and commercial payer coverage, reimbursement rates and payment practices may affect revenue and collections.
- Other risks: Competition and pricing pressure, Advanced Diagnostics contract cancellations or delays, laboratory capacity, cybersecurity and privacy, and reliance on timely specimen shipping could affect results.
- Financial reporting: Deloitte issued unqualified opinions on the financial statements and internal control over financial reporting; management also assessed disclosure controls as effective.
Important facts for investors to verify
- Current status and commercial effect of the RaDaR injunction and related patent litigation.
- Progress and any additional losses, penalties or remediation arising from the OIG/DOJ matter beyond the $11.2 million reserve.
- Whether revenue growth and margin gains continue, and whether positive adjusted EBITDA translates into sustained GAAP profitability and operating cash generation.
- Cash needs and refinancing or repayment plans for the $201.3 million notes due in 2025, alongside planned capital expenditures and restructuring costs.
- Actual timing, adoption and financial effects of new tests, LDT regulation, and changes in payer coverage and reimbursement.